4-[(1R,4R)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-N-hydroxybenzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-[(1R,4R)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-N-hydroxybenzamide
• 化学式: C₁₄H₁₉N₃O₂
• 分子量: 261.32
• InChiKey: PPLSUCYSSYZFBG-CHWSQXEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20160222026A1

  公开（公告）日：2016-08-04

  This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  本发明涉及用于抑制组蛋白去乙酰化酶的化合物。更具体地，本发明提供了式(I)中Q、J、L和Z所定义的化合物。
• METHODS OF TARGETED TREATMENT OF FRONTOTEMPORAL LOBAR DEGENERATION
  申请人：Patzke Holger

  公开号：US20140179678A1

  公开（公告）日：2014-06-26

  The present invention provides targeted treatment to subjects suffering from Frontotemporal lobar degeneration through use of FTLD targeted agents, as described in the present invention. In particular, the FTLD targeted agents provided herein demonstrate high brain penetration, which decreases risk issues associated with peripheral administration. Furthermore, the FTLD targeted agents of the present invention, when administered to a subject selected for treatment based on the results of a FTLD diagnostic assay, offer targeted treatment of FTLD.